| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On September 30, 2005
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1995S-0316
|
| 75-Day Premarket Notifications for New Dietary Ingredients
|
|
|
|
|
| 2004P-0266
|
| Take immediate action to cease the unlawful distribution of misbranded, adulterated and unlabeled cosmetics.
|
|
|
|
|
| 2004Q-0151
|
| Qualified Health Claim (QHC): soy protein and cancer
|
|
|
|
|
| 2005D-0288
|
| International Conference on Harmonisation; Draft Guidance on Q9 Quality Risk Management
|
|
|
|
|
| 2005D-0330
|
| Guidance for Industry and FDA Review Staff on Collection of Platelets by Automated Methods
|
|
|
|
|
| 2005N-0345
|
| Drug Approvals: Circumstances under which an active ingredient may be simultaneously marketed in both a prescription drug product and an over-the-counter drug product
|
|
|
|
|
| 2005P-0267
|
| Remove from label for propofol (Diprivan) the warning that propofol should be administered only by trained persons
|
|
|
|
|
| 2005P-0305
|
| Remove Dietary Supplements that Contain the Drug Pyridoxamine
|
|
|
|
|
| 2005P-0405
|
| Reclassification for Metal/Metal Semiconstrained Hip Joint Prostheses with Cemented or Uncemented Acetabular Components
|
|
|
|
|
| 1995S-0316
|
| 75-Day Premarket Notifications for New Dietary Ingredients
|
|
|
|
|
| RPT
291
|
| OYC International Inc
|
| Vol #:
|
| 214
|
|
|
|
|
| RPT
292
|
| Loders Croklaan BV
|
| Vol #:
|
| 214
|
|
|
|
|
| 2004P-0266
|
| Take immediate action to cease the unlawful distribution of misbranded, adulterated and unlabeled cosmetics.
|
|
|
|
|
| PDN
1
|
| HFC-1 to Environmental Working Group
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004Q-0151
|
| Qualified Health Claim (QHC): soy protein and cancer
|
|
|
|
|
| C
105
|
| Bariatric Weight Loss Center
|
| Vol #:
|
| 9
|
|
|
|
|
| 2005D-0288
|
| International Conference on Harmonisation; Draft Guidance on Q9 Quality Risk Management
|
|
|
|
|
| C
3
|
| Sanofi-Synthelabo Inc, Aventis Pharmaceuticals (Sanofi-Aventis)
|
| Vol #:
|
| 1
|
|
| |
|
| 2005D-0330
|
| Guidance for Industry and FDA Review Staff on Collection of Platelets by Automated Methods
|
|
|
|
|
| BKG
1
|
| Background Information
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005N-0345
|
| Drug Approvals: Circumstances under which an active ingredient may be simultaneously marketed in both a prescription drug product and an over-the-counter drug product
|
|
|
|
|
| C 21
|
| C Griffin
|
| Vol #:
|
| 1
|
|
|
|
|
| C 22
|
| L Squarzini
|
| Vol #:
|
| 1
|
|
|
|
|
| C 23
|
| R Van Slambrouck
|
| Vol #:
|
| 1
|
|
|
|
|
| C 24
|
| J P Freund
|
| Vol #:
|
| 1
|
|
|
|
|
| C 25
|
| J D Cahill
|
| Vol #:
|
| 1
|
|
|
|
|
| C 26
|
| M K Hopkins
|
| Vol #:
|
| 1
|
|
|
|
|
| C 27
|
| A L Neeter
|
| Vol #:
|
| 1
|
|
|
|
|
| C 28
|
| C Revoir
|
| Vol #:
|
| 1
|
|
|
|
|
| C 29
|
| M A Morris
|
| Vol #:
|
| 1
|
|
|
|
|
| C 30
|
| C Sacher
|
| Vol #:
|
| 1
|
|
|
|
|
| C 31
|
| Form Letter Count 16
|
| Vol #:
|
| 8
|
|
